news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Zhitong Finance APP learned that on July 16, Revolution Medicines (RVMD.US) announced the positive results of its phase 1b clinical trial of RMC-6236, a pan-RAS inhibitor under development. Analysis showed that RMC-6236 alone as a second-line therapy can prolong the median progression-free survival (PFS) of patients with KRAS G12X mutations by 8.1 months, and increase the disease control rate (DCR) of this patient population to nearly 90%. KRAS G12X refers to the conversion of glycine at the 12th position of the KRAS protein to other amino acids due to gene mutations. The company has begun preparing for a global randomized phase 3 clinical trial of the drug as a second-line therapy for PDAC patients.

According to Revolution Medicines, RMC-6236 is the first investigational targeted therapy for all major RAS mutations, which are the primary drivers of disease progression in PDAC.

Oncogenic RAS proteins drive up to 30% of all human cancers, with the greatest prominence in PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). RMC-6236 is an oral, selective inhibitor that targets mutant and wild-type RAS in the GTP-bound (active, ON) state.